SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Alexion Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
015351109
(CUSIP Number)
December 29, 2000
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Capital Research and Management Company
95-1411037
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE
INSTRUCTIONS) (a)
(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
5 SOLE VOTING POWER
NONE
6 SHARED VOTING POWER
NUMBER OF
SHARES
NONE
BENEFICIALL
Y OWNED BY
7 SOLE DISPOSITIVE POWER
EACH
REPORTING
920,000
PERSON
WITH:
8 SHARED DISPOSITIVE POWER
NONE
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
920,000 Beneficial ownership disclaimed pursuant to Rule 13d-4
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.1%
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IA
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
The Growth Fund of America, Inc.
52-0792143
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE
INSTRUCTIONS) (a)
(b)
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Maryland
5 SOLE VOTING POWER
920,000
6 SHARED VOTING POWER
NUMBER OF
SHARES
NONE
BENEFICIALL
Y OWNED BY
7 SOLE DISPOSITIVE POWER
EACH
REPORTING
NONE
PERSON
WITH:
8 SHARED DISPOSITIVE POWER
NONE
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
920,000
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.1%
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IV
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Schedule 13G
Under the Securities Exchange Act of 1934
Amendment No.
Item 1(a) Name of issuer:
Alexion Pharmaceuticals, Inc.
Item 1(b) Address of issuer's principal executive offices:
352 Knotter Drive
Cheshire, CT 06410
Item 2(a) Name of person(s) filing:
Capital Research and Management Company and The Growth Fund of
America, Inc.
Item 2(b) Address or principal business office or, if none, residence:
333 South Hope Street
Los Angeles, CA 90071
Item 2(c) Citizenship: N/A
Item 2(d) Title of class of securities:
Common Stock
Item 2(e) CUSIP No.:
015351109
Item 3 If this statement is filed pursuant to sections 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filings is a:
(d) [X] Investment Company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [X] An investment adviser in accordance with section
240.13d-1(b)(1)(ii)(E).
Item 4 Ownership
Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer identified
in Item 1.
See pages 2 and 3
(a) Amount beneficially owned:
(b) Percent of class:
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of:
(iv) Shared power to dispose or to direct the disposition of:
Capital Research and Management Company, an investment adviser
registered under Section 203 of the Investment Advisers Act of 1940
is deemed to be the beneficial owner of 920,000 shares or 5.1% of
the 18,016,000 shares of Common Stock believed to be outstanding as
a result of acting as investment adviser to various investment
companies registered under Section 8 of the Investment Company Act
of 1940.
The Growth Fund of America, Inc., an investment company registered
under the Investment Company Act of 1940, which is advised by
Capital Research and Management Company, is the beneficial owner of
920,000 shares or 5.1% of the 18,016,000 shares of Common Stock
believed to be outstanding.
Item 5 Ownership of 5 percent or Less of a Class. If this statement is
being filed to report the fact that as of the date hereof the
reporting person has ceased to be the beneficial owner of more than
5 percent of the class of securities, check the following: [ ]
Item 6 Ownership of More than 5% on Behalf of Another Person: N/A
Item 7 Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company or
Control Person.: N/A
Item 8 Identification and Classification of Members of the Group: N/A
Item 9 Notice of Dissolution of Group: N/A
Item 10 Certification
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
Signature
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement
is true, complete and correct.
Date: February 9, 2001
Signature: *Paul G. Haaga, Jr.
Name/Title: Paul G. Haaga, Jr., Executive Vice
President
Capital Research and Management Company
CUSIP: 015351109 Page 5 of 7
Date: February 9, 2001
Signature: *Paul G. Haaga, Jr.
Name/Title: Paul G. Haaga, Jr., Senior Vice President
The Growth Fund of America, Inc.
*By
James P. Ryan
Attorney-in-fact
Signed pursuant to a Power of Attorney dated December 19,
2000 included as an Exhibit to Schedule 13G filed with the
Securities and Exchange Commission by Capital Research and
Management Company on February 9, 2001 with respect to 3COM
Corporation.
CUSIP: 015351109 Page 6 of 7
AGREEMENT
Los Angeles, CA
February 9, 2001
Capital Research and Management Company ("CRMC") and The Growth Fund of
America, Inc. ("GFA") hereby agree to file a joint statement on Schedule
13G under the Securities Exchange Act of 1934 (the "Act") in connection
with their beneficial ownership of Common Stock issued by Alexion
Pharmaceuticals, Inc.
CRMC and GFA state that they are each entitled to individually use
Schedule 13G pursuant to Rule 13d-1(c) of the Act.
CRMC and GFA are each responsible for the timely filing of the statement
and any amendments thereto, and for the completeness and accuracy of the
information concerning each of them contained therein but are not
responsible for the completeness or accuracy of the information concerning
the others.
CAPITAL RESEARCH AND MANAGEMENT COMPANY
BY: *Paul G. Haaga, Jr.
Paul G. Haaga, Jr., Executive
Vice President
Capital Research and Management
Company
THE GROWTH FUND OF AMERICA, INC.
BY: *Paul G. Haaga, Jr.
Paul G. Haaga, Jr., Senior Vice
President
The Growth Fund of America,
Inc.
*By
James P. Ryan
Attorney-in-fact
Signed pursuant to a Power of Attorney dated December 19, 2000
included as an Exhibit to Schedule 13G filed with the Securities and
Exchange Commission by Capital Research and Management Company on
February 9, 2001 with respect to 3COM Corporation.